<DOC>
	<DOCNO>NCT00420381</DOCNO>
	<brief_summary>The purpose ass efficacy toxicity study agent , enzastaurin , patient recurrent persistent ovarian cancer .</brief_summary>
	<brief_title>Evaluation Enzastaurin Treatment Persistent Recurrent Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Patients must recurrent persistent epithelial ovarian primary peritoneal carcinoma . All patient must measurable disease . Patients must least one `` target lesion '' use assess response protocol . Patients must eligible high priority GOG protocol , one exists . Patients receive one prior regimen must GOG Performance Status 0 , 1 , 2 . Patients receive two prior regimen must GOG Performance Status 0 1 . Any hormonal therapy direct malignant tumor must discontinue least one week prior registration . Continuation hormone replacement therapy permit . Any prior therapy direct malignant tumor , include immunologic agent , must discontinue least four week prior registration . Patients must one prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound . Patients must NOT receive noncytotoxic therapy management recurrent persistent disease . Patients childbearing potential must negative serum pregnancy test prior study entry practice effective form contraception ( example , intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month discontinuation study treatment . Patients previous enzastaurin treatment . Patients receive radiation 25 % marrowbearing area Patients invasive malignancy , exception nonmelanoma skin cancer , ( ) evidence cancer present within last 5 year whose previous cancer treatment contraindicate protocol therapy . Patients receive treatment within last 30 day drug receive regulatory approval indication time study entry . Patients unable discontinue use carbamazepine , phenobarbital , phenytoin ( refer Concomitant Medications discussion enzyme induce antiepileptic drug [ EIAEDs ] ) . Patients receive concurrent administration systemic anticancer therapy except biphosphonate patient bony metastasis . Patients receive prior therapy noncytotoxic agent ( i.e . bevacizumab ) . Patients serious concomitant systemic disorder ( example , active infection abnormal electrocardiogram ( ECG ) indicative cardiac disease ) , opinion investigator , would compromise safety patient his/her ability complete study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Recurrent Cancer</keyword>
</DOC>